HRT Financial’s Cytokinetics CYTK Stock Holding History

HRT Financial’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.43M	Buy	+36,900	New	+$2.35M	0.01%	1480

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HRT Financial's CYTK Position: Q1 2026 in Review

HRT Financial sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 23,376 shares — an estimated $1.49M sold.

HRT Financial first reported a position in CYTK in Q2 2021 and held it in 6 quarters. The position peaked at $30.2M in Q1 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

HRT Financial reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 23,376 Cytokinetics shares in Q1 2026, an estimated $1.49M.
HRT Financial first reported a position in Cytokinetics in Q2 2021 and held it in 6 quarters.
HRT Financial's Cytokinetics position peaked at $30.2M in Q1 2024.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.